Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

PURPOSE: Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in the Phase 3 studies MONARCH 2 (fulvestrant as ET) and MONARCH 3 (letrozole or anastrozole as ET). Here, we report age-specific safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Goetz, Matthew P., Okera, Meena, Wildiers, Hans, Campone, Mario, Grischke, Eva-Maria, Manso, Luis, André, Valérie A. M., Chouaki, Nadia, San Antonio, Belén, Toi, Masakazu, Sledge, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990838/
https://www.ncbi.nlm.nih.gov/pubmed/33392835
http://dx.doi.org/10.1007/s10549-020-06029-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990838/
https://www.ncbi.nlm.nih.gov/pubmed/33392835
http://dx.doi.org/10.1007/s10549-020-06029-y

Ejemplares similares